Are genomics stocks a good investment?

Other investors find them too volatile, particularly gene-editing stocks with prices often in a lull for long periods then moving strongly up or down in a single day, depending on the outcome of clinical trials. From a higher-level perspective, genomics companies can look like the technology companies many investors love.

How big is the gene-editing market?

Gene-editing companies have the potential to treat and even cure diseases caused by genetic variants. The gene-editing market is projected to reach $15 billion by 2028. Data source: The Motley Fool. Data current as of March 5, 2024. Industry leader in DNA short-read sequencing technology. Champion of DNA long-read sequencing technology.

How much does it cost to map our DNA?

It initially took 13 years and $2.7 billion (in 1991 dollars) to map our DNA as part of the Human Genome Project. Since then, more sophisticated next-generation sequencing (NGS) technology enables an entire genome to be sequenced within a single day at a cost of less than $600.